Article Text

Download PDFPDF
CASE REPORT
Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases
  1. Simon Gray,
  2. Xiao Ying Khor and
  3. Dennis Yiannakis
  1. Department of Clinical Oncology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK
  1. Correspondence to Dr Dennis Yiannakis, simon.james.gray4{at}gmail.com

Abstract

Ovarian cancer is the second the most common gynaecological malignancy in developed countries. 70% of patients relapse in the first 3 years following debulking surgery and first-line chemotherapy. Niraparib is a poly adenosine diphosphate ribose polymerase inhibitor which uses the concept of synthetic lethality in the presence of a mutation in the breast cancer susceptibility gene (BRCA), and is now recommended as maintenance treatment in patients with platinum-sensitive relapse of ovarian cancer. It has been shown to increase progression-free survival. We present a case of a 68-year-old woman with brain metastases from high-grade serous ovarian cancer who has remained free of disease progression for longer than 17 months with niraparib use as maintenance treatment after second-line chemotherapy.

  • gynecological cancer
  • malignant disease and immunosuppression
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors SG: critically revised work for important intellectual content including bulk of discussion, wrote multiple subsequent drafts. XYK: clinically involved in caring for the patient; wrote first draft. DY: responsible clinician for patient; guided desirable inclusions and involved in redrafting process with suggestions which shaped the content of the piece.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.